| Literature DB >> 33714545 |
Zhiyu Yang1, Hanrui Wu1, Phil H Lee2, Fotis Tsetsos3, Lea K Davis4, Dongmei Yu2, Sang Hong Lee5, Søren Dalsgaard6, Jan Haavik7, Csaba Barta8, Tetyana Zayats9, Valsamma Eapen10, Naomi R Wray11, Bernie Devlin12, Mark Daly13, Benjamin Neale14, Anders D Børglum15, James J Crowley16, Jeremiah Scharf2, Carol A Mathews17, Stephen V Faraone18, Barbara Franke19, Manuel Mattheisen20, Jordan W Smoller21, Peristera Paschou22.
Abstract
BACKGROUND: Tourette syndrome (TS) is often found comorbid with other neurodevelopmental disorders across the impulsivity-compulsivity spectrum, with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) as most prevalent. This points to the possibility of a common etiological thread along an impulsivity-compulsivity continuum.Entities:
Keywords: ADHD; ASD; Cross-disorder genetic analysis; GWAS meta-analysis; OCD; Tourette syndrome
Mesh:
Year: 2021 PMID: 33714545 PMCID: PMC9152955 DOI: 10.1016/j.biopsych.2020.12.028
Source DB: PubMed Journal: Biol Psychiatry ISSN: 0006-3223 Impact factor: 12.810
Pairwise Genetic Correlation
| Disorder Pairs | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| ADHD/ASD | ADHD/OCD | ADHD/TS | ASD/OCD | ASD/TS | OCD/TS | |
|
| ||||||
| #SNPs | 1,042,563 | 1,030,018 | 1,062,415 | 1,012,959 | 1,044,625 | 1,100,873 |
|
| ||||||
|
| .35 | −.17 | .26 | .12 | .18 | .38 |
|
| ||||||
| SE | .05 | .07 | .06 | .08 | .06 | .10 |
|
| ||||||
| 1.33 × 10−11 | 2.00 × 10−2 | 2.05 × 10−5 | 1.50 × 10−1 | 5.50 × 10−3 | 2.00 × 10−4 | |
LD score regression analysis showing pairwise genetic correlation across ADHD, ASD, OCD, and TS. #SNPs indicates the number of overlapping SNPs used in the analysis. r is the genetic correlation; SE and p are the standard error and p value for rg, respectively.
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; LD, linkage disequilibrium; OCD, obsessive-compulsive disorder; SNP, single nucleotide polymorphism; TS, Tourette syndrome.
Figure 1.Genetic architecture and causality relationships across disorders of interest. (A) Investigating the existence of a common factor F across all four disorders using genomic structural equation modeling. Path graph shows loads and corresponding standard errors in parenthesis. Circular arrows denote the residual genetic variance not explained by the common factor. See Table S1 in Supplement 2. (B) Network plot indicating the causality across four disorders estimated using generalized summary data–based Mendelian randomization. Solid arrows indicate a significant causality relationship, while dash arrows indicate insignificant relationships. Numbers on the arrow indicate effect size and estimation standard error (in parenthesis). See Table S2 in Supplement 2. ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; OCD, obsessive-compulsive disorder; TS, Tourette syndrome; u, residual variance not explained by common factor F.
Figure 2.Manhattan plots and QQ plots for cross-disorder genome-wide association study meta-analyses. An asterisk (*) indicates genes hosting SNPs with m-value > 0.9 in all disorders analyzed, and a red circle denotes a novel region that was not previously reported associated with the disorder of interest. (A) TS-ADHD-ASD genome-wide association study meta-analysis. (B) TS-OCD genome-wide association study meta-analysis. See Tables S3 and S4 in Supplement 2. ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; OCD, obsessive-compulsive disorder; SNP, single nucleotide polymorphism; TS, Tourette syndrome.
Comparison of Results Across Regions That Are Shown as Genome-wide Significant and Pleiotropic in Either the TS-ADHD-ASD GWAS Meta-analysis (SNP-Based or Gene-Based) or the PGC Eight-Disorder GWAS Meta-analysis
| SNP-Based Results | Gene-Based Results | Cross-Disorder Group of the Psychiatric Genomics Consortium | Original TS GWAS | Original ADHD GWAS | Original ASD GWAS | ||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Region | Leading SNP | Gene | Leading SNP | Leading SNP | Leading SNP | Leading SNP | |
|
| |||||||
| 2p15[ | 1.22 × 10−7/1.05 |
| 6.08 × 10−8 | 2.40 × 10−6/0.94 | 9.34 × 10−4 | 7.27 × 10−5 | 8.61 × 10−6 |
|
| |||||||
|
| 7.59 × 10−7 | ||||||
|
| |||||||
| 2q24.1[ | 1.22 × 10−7/1.05 |
| 8.43 × 10−8 | 2.07 × 10−8/1.03[ | 2.30 × 10−5 | 3.36 × 10−5 | 9.30 × 10−7 |
|
| |||||||
| 3q13.12[ | 1.86 × 10−8/1.05[ | 9.46 × 10−7/1.05 | 9.44 × 10−6 | 2.20 × 10−6 | 1.51 × 10−4 | ||
|
| |||||||
| 3p21.31[ | 1.71 × 10−7/0.96 |
| 1.69 × 10−7 | 4.06 × 10−8/1.03[ | 1.80 × 10−5 | 6.74 × 10−7 | 3.51 × 10−5 |
|
| |||||||
|
| 5.54 × 10−7 | ||||||
|
| |||||||
|
| 1.00 × 10−6 | ||||||
|
| |||||||
|
| 1.09 × 10−6 | ||||||
|
| |||||||
| 4p13[ | 9.29 × 10−5/1.04 | 3.00 × 10−10/0.97[ | 2.28 × 10−4 | 4.38 × 10−4 | 3.08 × 10−5 | ||
|
| |||||||
| 4q24[ | 1.51 × 10−7/0.96 |
| 1.12 × 10−7 | 1.11 × 10−10/0.87[ | 3.03 × 10−4 | 6.48 × 10−8 | 1.39 × 10−5 |
|
| |||||||
|
| 1.35 × 10−6 | ||||||
|
| |||||||
| 5q14.3[ | 2.98 × 10−11/0.95[ | 1.64 × 10−9/0.92[ | 3.71 × 10−5 | 1.81 × 10−8[ | 1.92 × 10−6 | ||
|
| |||||||
| 5q21.2[ | 3.56 × 10−11/1.06[ | 1.55 × 10−16/1.03[ | 8.66 × 10−4 | 1.08 × 10−7 | 3.25 × 10−7 | ||
|
| |||||||
| 7q11.22[ | 7.17 × 10−7/0.96 |
| 1.15 × 10−6 | 3.22 × 10−6/0.98 | 4.01 × 10−4 | 3.96 × 10−6 | 4.02 × 10−6 |
|
| |||||||
| 10q25.1[ | 5.61 × 10−9/1.06[ |
| 4.97 × 10−10 | 9.97 × 10−13/1.03[ | 1.67 × 10−4 | 1.76 × 10−8 | 1.15 × 10−4 |
|
| |||||||
| 13q22.3[ | 4.03 × 10−9/0.95[ | - | - | 1.16 × 10−7/0.97 | 2.46 × 10−3 | 5.07 × 10−7 | 1.76 × 10−5 |
|
| |||||||
| 14q13.1[ | 3.99 × 10−8/0.94[ | - | - | 5.11 × 10−10/0.94[ | 3.04 × 10−4 | 1.02 × 10−5 | 3.08 × 10−4 |
|
| |||||||
| 16p13.3[ | 3.72 × 10−5/0.96 | - | - | 5.59 × 10−11/0.97[ | 2.81 × 10−5 | 1.06 × 10−5 | 1.92 × 10−4 |
|
| |||||||
| 17q21.31[ | 3.22 × 10−8/0.95[ |
| 4.52 × 10−7 | 3.28 × 10−6/0.92 | 6.53 × 10−5 | 3.79 × 10−4 | 2.89 × 10−7 |
|
| |||||||
|
| 7.98 × 10−8 | ||||||
|
| |||||||
|
| 2.32 × 10−7 | ||||||
|
| |||||||
|
| 8.72 × 10−7 | ||||||
|
| |||||||
| 18q21.2[ | 1.17 × 10−5/0.97 | - | - | 4.26 × 10−12/1.03[ | 3.29 × 10−4 | 1.89 × 10−5 | 7.05 × 10−5 |
|
| |||||||
| 20p11.23-p11.24[ | 1.71 × 10−9/1.05[ |
| 2.33 × 10−9 | 2.72 × 10−10/1.05[ | 1.08 × 10−3 | 1.33 × 10−6 | 2.04 × 10−9 |
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; GWAS, genome-wide association study; OR, odds ratio; PGC, Psychiatric Genomics Consortium; SNP, single nucleotide polymorphism; TS, Tourette syndrome.
Novel regions that are only identified as genome-wide significant and pleiotropic in this study (i.e., crossing genome-wide significance threshold and m-value > 0.9 across TS-ADHD-ASD).
SNP/gene that is genome-wide significant and pleiotropic.
Genome-wide significant.
Regions where criteria are satisfied only in the PGC eight-disorder GWAS meta-analysis.
Regions identified in both studies.
Comparison of Results Across Regions That Are Shown as Genome-wide Significant and Pleiotropic in Either the TS-OCD GWAS Meta-analysis (SNP-Based or Gene-Based) or the PGC Eight-Disorder GWAS Meta-analysis
| SNP-Based Results | Gene-Based Results | Cross-Disorder Group of the Psychiatric Genomics Consortium | Original TS GWAS | Original OCD GWAS | ||
|---|---|---|---|---|---|---|
|
|
|
|
|
| ||
| Region | Leading SNP | Gene | Leading SNP | Leading SNP | Leading SNP | |
|
| ||||||
| 1p31.1[ | 1.32 × 10−4/1.34 | 3.63 × 10−11/1.03[ | 1.69 × 10−4 | 2.26 × 10−4 | ||
|
| ||||||
| 2p16.1[ | 5.64 × 10−9/0.89[ | 2.34 × 10−14/0.97[ | 4.76 × 10−8 | 2.03 × 10−4 | ||
|
| ||||||
| 3p12.1[ | 1.06 × 10−6/1.12 |
| 3.99 × 10−7 | 5.74 × 10−5/1.05 | 8.36 × 10−5 | 1.15 × 10−4 |
|
| ||||||
| 4p13[ | 4.03 × 10−4/1.11 | 5.59 × 10−9/0.96[ | 2.28 × 10−4 | 6.04 × 10−5 | ||
|
| ||||||
| 6p21.33[ | 1.48 × 10−7/0.81 |
| 7.64 × 10−7 | 3.63 × 10−14/0.97[ | 1.56 × 10−5 | 1.55 × 10−5 |
|
| ||||||
|
| 7.98 × 10−7 | |||||
|
| ||||||
|
| 1.54 × 10−6 | |||||
|
| ||||||
| 14q32.33[ | 6.22 × 10−4/0.93 | - | - | 5.20 × 10−9/1.03[ | 6.36 × 10−4 | 1.40 × 10−4 |
|
| ||||||
| 16p13.3[ | 9.21 × 10−5/0.92 | - | - | 5.59 × 10−11/0.97[ | 2.81 × 10−5 | 9.12 × 10−5 |
|
| ||||||
| 18q21.2[ | 5.74 × 10−4/0.86 | - | - | 4.26 × 10−12/1.03[ | 3.29 × 10−4 | 3.99 × 10−4 |
|
| ||||||
| 22q13.2[ | 1.23 × 10−5/0.90 | - | - | 5.36 × 10−14/1.04[ | 6.84 × 10−6 | 9.92 × 10−4 |
GWAS, genome-wide association study; OCD, obsessive-compulsive disorder; OR, odds ratio; PGC, Psychiatric Genomics Consortium; SNP, single nucleotide polymorphism; TS, Tourette syndrome.
Regions where criteria are satisfied only in the PGC eight-disorder GWAS meta-analysis.
SNP/gene that is genome-wide significant and pleiotropic.
Genome-wide significant.
Novel regions that are only identified as genome-wide significant and pleiotropic in this study (i.e., crossing genome-wide significance threshold and m-value > 0.9 across TS-OCD).
Regions identified in both studies.
Figure 3.Manhattan plots for gene-based genome-wide association study meta-analyses. An asterisk (*) indicates that genes stay significant when only analyzing SNPs with m-value. 0.9 in all disorders analyzed, and a red circle denotes novel genes that could not be picked up through gene-based analysis using summary statistics from individual disorders alone. (A) TS-ADHD-ASD gene-based analysis. (B) TS-OCD gene-based analysis. See Table S9 in Supplement 2. ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; OCD, obsessive-compulsive disorder; SNP, single nucleotide polymorphism; TS, Tourette syndrome
Figure 4.Top 10 gene networks from top 200 genes annotated from SNP-based genome-wide association study meta-analyses results. (A) TS-ADHDASD– based network plot. (B) TS-OCD-SNP–based network plot. ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; OCD, obsessive-compulsive disorder; SNP, single nucleotide polymorphism; TS, Tourette syndrome.
KEY RESOURCES TABLE
| Resource Type | Specific Reagent or Resource | Source or Reference | Identifiers | Additional Information |
| Add additional rows as needed for each resource type | Include species and sex when applicable. | Include name of manufacturer, company, repository, individual, or research lab. Include PMID or DOI for references; use “this paper” if new. | Include catalog numbers, stock numbers, database IDs or accession numbers, and/or RRIDs. RRIDs are highly encouraged; search for RRIDs at | Include any additional information or notes if necessary. |
| Antibody | ||||
| Bacterial or Viral Strain | ||||
| Biological Sample | ||||
| Cell Line | ||||
| Chemical Compound or Drug | ||||
| Commercial Assay Or Kit | ||||
| Deposited Data; Public Database | ADHD European Ancestry GWAS summary statistics | publication doi: | Downloaded from | |
| ASD European Ancestry GWAS summary statistics | publication doi: | Downloaded from | ||
| OCD GWAS summary statistics | publication doi: | downloaded from | ||
| TS GWAS summary statistics | publication doi: | provided by collaborator, who is an author of the publication refered | ||
| Genetic Reagent | ||||
| Organism/Strain | ||||
| Peptide, Recombinant Protein | ||||
| Recombinant DNA | ||||
| Sequence-Based Reagent | ||||
| Software; Algorithm | ASSET (DOI: | |||
| FUMA platform (DOI: | ||||
| Genomic SEM (DOI: | ||||
| GSMR (DOI: | ||||
| mtCOJO (DOI: | ||||
| LDSC (DOI: | reference filesdownloaded from | |||
| metasoft (DOI: | ||||
| SMR (DOI: | ||||
| Transfected Construct | ||||
| Other |